LGVN compared with NERV: revenue, margins and what each company keeps, and the suppliers and customers both name

LGVNLongeveron Inc.

Mkt capRevenueRevenue

NERVMinerva Neurosciences, Inc.

Mkt capRevenueRevenue

Compare

LGVNLongeveron Inc.

NERVMinerva Neurosciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

LGVN: latest quarter is a loss; flow not drawable. NERV: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LGVN 1

—The University of Miamiunlistedsupplier

Shared 0

No shared counterparties.

Only NERV 7

RPRXRoyalty Pharma plc ("Royalty Pharma")customer

—Catalentunlistedsupplier

—Catalent Germany Schorndorf GmbHunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Dr. Inderjit Kaul

unlistedsupplier

3 more · NERV chain ›

Price

rebased to 0%

LGVN, solidNERV, dashed

LGVNLongeveron Inc.

1.78▲+1.71%· post 1.78

Mkt cap$5.2MRevenue$287,000Q2 FY26Revenue$1MFY25

NERVMinerva Neurosciences, Inc.

2.30▲+2.73%· post 2.30

ClosedOct 30 '26

Mkt cap$110.8MRevenue—Revenue—

Compare

ClosedOct 30 '26

LGVNLongeveron Inc.

NERVMinerva Neurosciences, Inc.

1.78▲+1.71%post 1.78

Price

2.30▲+2.73%post 2.30

$5.2M

Mkt cap

$110.8M

Q2 FY26$287,000

Revenue

—

FY25$1M

Revenue

—

LGVN1.78▲+1.71%vsNERV2.30▲+2.73%ClosedOct 30 '26